Search Results - "KOCH, Birgit C. P"

Refine Results
  1. 1

    Alternative Sampling Devices to Collect Dried Blood Microsamples: State-of-the-Art by Delahaye, Lisa, Veenhof, Herman, Koch, Birgit C. P., Alffenaar, Jan-Willem C., Linden, Rafael, Stove, Christophe

    Published in Therapeutic drug monitoring (01-06-2021)
    “…Dried blood spots (DBS) have been used in newborn screening programs for several years. More recently, there has been growing interest in using DBS as a home…”
    Get full text
    Journal Article
  2. 2
  3. 3

    Barriers and facilitators for therapeutic drug monitoring of beta-lactams and ciprofloxacin in the ICU: a nationwide cross-sectional study by Ewoldt, Tim M. J, Abdulla, Alan, van den Broek, Puck, Hunfeld, Nicole, Bahmany, Soma, Muller, Anouk E, Gommers, Diederik, Polinder, Suzanne, Endeman, Henrik, Spronk, Inge, Koch, Birgit C. P

    Published in BMC infectious diseases (13-07-2022)
    “…Abstract Background Recent studies demonstrated that failure of achieving pharmacodynamic targets of commonly used antibiotics is common in critically ill…”
    Get full text
    Journal Article
  4. 4
  5. 5

    Clinical Experience with Off-Label Intrathecal Administration of Selected Antibiotics in Adults: An Overview with Pharmacometric Considerations by Muller, Anouk E, van Vliet, Peter, Koch, Birgit C. P

    Published in Antibiotics (Basel) (01-08-2023)
    “…Drain-associated intracerebral infections are life-threatening emergencies. Their treatment is challenging due to the limited penetration of antibiotics to the…”
    Get full text
    Journal Article
  6. 6

    Improving the tolerability of osimertinib by identifying its toxic limit by Agema, Bram C., Veerman, G. D. Marijn, Steendam, Christi M. J., Lanser, Daan A. C., Preijers, Tim, van der Leest, Cor, Koch, Birgit C. P., Dingemans, Anne-Marie C., Mathijssen, Ron H. J., Koolen, Stijn L. W.

    “…Background: Osimertinib is the cornerstone in the treatment of epidermal growth factor receptor-mutated non-small cell lung cancer (NSCLC). Nonetheless, ±25%…”
    Get full text
    Journal Article
  7. 7
  8. 8
  9. 9
  10. 10

    Meropenem Model-Informed Precision Dosing in the Treatment of Critically Ill Patients: Can We Use It? by Li, Letao, Sassen, Sebastiaan D T, Ewoldt, Tim M J, Abdulla, Alan, Hunfeld, Nicole G M, Muller, Anouk E, de Winter, Brenda C M, Endeman, Henrik, Koch, Birgit C P

    Published in Antibiotics (Basel) (01-02-2023)
    “…The number of pharmacokinetic (PK) models of meropenem is increasing. However, the daily role of these PK models in the clinic remains unclear, especially for…”
    Get full text
    Journal Article
  11. 11
  12. 12

    Pharmacodynamics of Flucloxacillin in a Neutropenic Murine Thigh Infection Model: A Piece of the Puzzle towards Evidence-Based Dosing by Roelofsen, Eveline E, de Winter, Brenda C M, van der Spek, Heleen, Snijders, Susan, Koch, Birgit C P, van den Berg, Sanne, Muller, Anouk E

    Published in Antibiotics (Basel) (03-08-2022)
    “…For decades, flucloxacillin has been used to treat methicillin-susceptible Staphylococcus aureus (MSSA). Little is still known about its pharmacodynamics (PD)…”
    Get full text
    Journal Article
  13. 13
  14. 14

    Using Fluorescence Polarization Immunoassay for Determination of Erythrocyte Methotrexate Polyglutamates, a Quick and Easy Test? by DEN BOER, Ethan, KOCH, Birgit C. P, HUISMAN, Ruud, DE JONGE, Robert

    Published in Therapeutic drug monitoring (01-12-2014)
    “…The folate antagonist methotrexate (MTX) is the anchor drug in the treatment of rheumatoid arthritis. The therapeutic effects of MTX are attributed to the…”
    Get full text
    Journal Article
  15. 15

    Clinical Pharmacokinetics of Fosfomycin after Continuous Infusion Compared with Intermittent Infusion: a Randomized Crossover Study in Healthy Volunteers by Al Jalali, Valentin, Matzneller, Peter, Wulkersdorfer, Beatrix, Chou, Scharon, Bahmany, Soma, Koch, Birgit C P, Zeitlinger, Markus

    Published in Antimicrobial agents and chemotherapy (16-12-2020)
    “…Continuous infusion (CON) of fosfomycin has been proposed as potentially advantageous in certain clinical scenarios. However, no clinical data on the…”
    Get full text
    Journal Article
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20

    Non-linear absorption pharmacokinetics of amoxicillin: consequences for dosing regimens and clinical breakpoints by de Velde, Femke, de Winter, Brenda C M, Koch, Birgit C P, van Gelder, Teun, Mouton, Johan W

    Published in Journal of antimicrobial chemotherapy (01-10-2016)
    “…To describe the population pharmacokinetics of oral amoxicillin and to compare the PTA of current dosing regimens. Two groups, each with 14 healthy male…”
    Get full text
    Journal Article